TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.
TD Cowen analyst Michael Nedelcovych maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $65 to $68.